Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| non-classical monocyte | 23 studies | 35% ± 12% | |
| classical monocyte | 23 studies | 34% ± 14% | |
| monocyte | 19 studies | 26% ± 8% | |
| macrophage | 14 studies | 22% ± 8% | |
| neutrophil | 7 studies | 32% ± 11% | |
| conventional dendritic cell | 6 studies | 29% ± 11% | |
| dendritic cell | 5 studies | 27% ± 14% | |
| myeloid cell | 4 studies | 27% ± 13% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| peripheral blood | 3 studies | 21% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| lung | 100% | 3240.46 | 578 / 578 | 99% | 7.70 | 1139 / 1155 |
| intestine | 83% | 316.72 | 803 / 966 | 87% | 4.00 | 459 / 527 |
| bladder | 90% | 425.00 | 19 / 21 | 79% | 4.28 | 399 / 504 |
| breast | 76% | 327.78 | 350 / 459 | 90% | 3.35 | 1002 / 1118 |
| liver | 80% | 321.04 | 181 / 226 | 77% | 2.45 | 312 / 406 |
| kidney | 65% | 280.38 | 58 / 89 | 89% | 5.87 | 803 / 901 |
| esophagus | 59% | 211.88 | 857 / 1445 | 93% | 4.12 | 171 / 183 |
| thymus | 69% | 214.65 | 449 / 653 | 80% | 2.45 | 484 / 605 |
| adrenal gland | 92% | 442.92 | 238 / 258 | 50% | 1.38 | 115 / 230 |
| uterus | 49% | 153.88 | 83 / 170 | 88% | 3.79 | 404 / 459 |
| prostate | 64% | 238.60 | 158 / 245 | 71% | 1.48 | 354 / 502 |
| stomach | 43% | 187.79 | 153 / 359 | 89% | 4.76 | 255 / 286 |
| pancreas | 36% | 131.12 | 117 / 328 | 94% | 7.24 | 167 / 178 |
| ovary | 33% | 93.62 | 59 / 180 | 86% | 2.72 | 369 / 430 |
| skin | 12% | 30.23 | 225 / 1809 | 92% | 5.82 | 433 / 472 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 16.82 | 29 / 29 |
| spleen | 100% | 5789.08 | 241 / 241 | 0% | 0 | 0 / 0 |
| adipose | 97% | 876.01 | 1172 / 1204 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 96% | 4.80 | 43 / 45 |
| peripheral blood | 85% | 22517.52 | 788 / 929 | 0% | 0 | 0 / 0 |
| brain | 17% | 55.65 | 445 / 2642 | 60% | 2.61 | 422 / 705 |
| heart | 66% | 264.73 | 572 / 861 | 0% | 0 | 0 / 0 |
| blood vessel | 64% | 342.73 | 856 / 1335 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 45% | 1.06 | 36 / 80 |
| muscle | 13% | 28.06 | 101 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0002250 | Biological process | adaptive immune response |
| GO_0045671 | Biological process | negative regulation of osteoclast differentiation |
| GO_0002764 | Biological process | immune response-regulating signaling pathway |
| GO_0006952 | Biological process | defense response |
| GO_0007166 | Biological process | cell surface receptor signaling pathway |
| GO_0030667 | Cellular component | secretory granule membrane |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0004888 | Molecular function | transmembrane signaling receptor activity |
| GO_0038023 | Molecular function | signaling receptor activity |
| GO_0001540 | Molecular function | amyloid-beta binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | LILRB3 |
| Protein name | Leukocyte immunoglobulin-like receptor subfamily B member 3 (LIR-3) (Leukocyte immunoglobulin-like receptor 3) (CD85 antigen-like family member A) (Immunoglobulin-like transcript 5) (ILT-5) (Monocyte inhibitory receptor HL9) (CD antigen CD85a) Leukocyte immunoglobulin like receptor B3 Leukocyte immunoglobulin-like receptor subfamily B member 3 Leukocyte immunoglobulin like receptor B3 (Leukocyte immunoglobulin-like receptor subfamily B member 3) LILRB3 |
| Synonyms | ILT5 LIR3 |
| Description | FUNCTION: May act as receptor for class I MHC antigens. Becomes activated upon coligation of LILRB3 and immune receptors, such as FCGR2B and the B-cell receptor. Down-regulates antigen-induced B-cell activation by recruiting phosphatases to its immunoreceptor tyrosine-based inhibitor motifs (ITIM). . |
| Accessions | ENST00000445347.2 ENST00000611086.4 [O75022-1] A0A0G2JN08 U5QBH7 A0A0G2JMM1 U5QBH1 ENST00000616782.4 A0A0G2JLT7 U5QB82 ENST00000346401.10 U5QBI2 ENST00000613710.4 O75022 U5QEV1 ENST00000622537.4 U5QB77 A0A0G2JPK5 A0A0G2JMZ3 ENST00000621660.4 U5XI30 U5XJY1 U5XI32 U5QEM4 A0A0G2JN67 ENST00000245620.13 U5XJY8 A0A0G2JPI7 A0A0G2JNW3 ENST00000391750.5 U5QEU5 U5XHC8 U5XH15 U5QB73 A0A0G2JNB3 ENST00000622504.4 F8WD89 U5XHC3 ENST00000615764.4 ENST00000613833.4 A0A0G2JM46 ENST00000614546.4 F8W6G6 U5XKH1 C9JWL8 U5QEM8 ENST00000610675.4 ENST00000414379.5 U5QBC5 ENST00000612057.4 ENST00000613698.4 A0A0G2JPG2 ENST00000619617.4 U5XHD3 ENST00000615387.4 U5XJY5 ENST00000616493.4 U5QBD0 A0A0G2JLU2 |
